39798-19-1

Basic information

• Product Name: (αR)-6-Amino-α-[(1R)-1-formyl-2-hydroxyethoxy]-9H-purine-9-acetaldehyde
• Synonyms: (αR)-6-Amino-α-[(1R)-1-formyl-2-hydroxyethoxy]-9H-purine-9-acetaldehyde;9-[(R)-1-[[(R)-1-Formyl-2-hydroxyethyl]oxy]-2-oxoethyl]-9H-purin-6-amine;Adenosine dialdehyde;Ado dialdehyde;9H-Purine-9-acetaldehyde, 6-amino-alpha-(1-formyl)-2-(hydroxyethoxy)-, (R-(R*,R*))-
• CAS NO: 39798-19-1
• Molecular Formula: C₁₀H₁₁N₅O₄
• Molecular Weight: 265.22544
• Mol File: 39798-19-1.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 532.9°Cat760mmHg
• Flash Point: 276.1°C
• Appearance: /
• Density: 1.69g/cm³
• Vapor Pressure: 3.46E-12mmHg at 25°C
• Refractive Index: 1.729
• CAS DataBase Reference: (αR)-6-Amino-α-[(1R)-1-formyl-2-hydroxyethoxy]-9H-purine-9-acetaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: (αR)-6-Amino-α-[(1R)-1-formyl-2-hydroxyethoxy]-9H-purine-9-acetaldehyde(39798-19-1)
• EPA Substance Registry System: (αR)-6-Amino-α-[(1R)-1-formyl-2-hydroxyethoxy]-9H-purine-9-acetaldehyde(39798-19-1)

Safety Data

• Hazardous Substances Data: 39798-19-1(Hazardous Substances Data)

Usage

General Description

The chemical compound "(αR)-6-Amino-α-[(1R)-1-formyl-2-hydroxyethoxy]-9H-purine-9-acetaldehyde" is a derivative of purine, a heterocyclic aromatic organic compound. It contains an amino group and a formyl group attached to the purine ring, as well as an aldehyde group attached to a carbon atom in the purine structure. The compound also features a hydroxyethoxy group, which is a hydroxyl group attached to an ethoxy group. This complex structure gives "(αR)-6-Amino-α-[(1R)-1-formyl-2-hydroxyethoxy]-9H-purine-9-acetaldehyde" potential biological activity and may make it useful for pharmaceutical or research purposes.

InChI:InChI=1/C10H11N5O4/c11-9-8-10(13-4-12-9)15(5-14-8)7(3-18)19-6(1-16)2-17/h1,3-7,17H,2H2,(H2,11,12,13)/t6-,7+/m0/s1

Upstream product

• 58-61-7 adenosine 

Downstream Products

• 21794-55-8 (+)-Daunomycinone 
• 183051-91-4 (2R,4aR,6R,7R,8R,8aS)-6-(6-Amino-purin-9-yl)-8-nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-7-ol 
• 183051-92-5 (2S,4aR,6R,7R,8R,8aR)-6-(6-Amino-purin-9-yl)-8-nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-7-ol 
• 183051-90-3 (2R,4aR,6R,7S,8R,8aS)-6-(6-Amino-purin-9-yl)-8-nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-7-ol 
• 183051-93-6 9-((2R,4aR,6R,8R,8aS)-8-Nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183051-95-8 9-((2R,4aR,6R,8aS)-8-Nitro-2-phenyl-4,4a,6,8a-tetrahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183052-01-9 9-((2R,4aR,6R,7R,8S,8aS)-7-Methylsulfanyl-8-nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183051-98-1 9-((2R,4aR,6R,7R,8R,8aS)-7-Allylamino-8-nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183051-99-2 9-((2R,4aR,6R,7R,8R,8aS)-8-Nitro-2-phenyl-7-prop-2-ynylamino-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183051-97-0 9-((2R,4aR,6R,7R,8R,8aS)-8-Nitro-2-phenyl-7-piperidin-1-yl-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183051-96-9 9-((2R,4aR,6R,7R,8R,8aS)-7-Morpholin-4-yl-8-nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183052-02-0 9-((2R,4aR,6R,7R,8S,8aS)-8-Nitro-2-phenyl-7-phenylsulfanyl-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 
• 183052-00-8 [(2R,4aR,6R,7R,8R,8aS)-6-(6-Amino-purin-9-yl)-8-nitro-2-phenyl-hexahydro-pyrano[3,2-d][1,3]dioxin-7-ylamino]-acetic acid methyl ester 
• 205926-83-6 9-((2R,4aR,6R,7R,8R,8aS)-8-Nitro-2-phenyl-7-pyrrolidin-1-yl-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl)-9H-purin-6-ylamine 

Relevant articles and documents

-

-

Daunorubicin derivatives obtained from daunorubicin and nucleoside dialdehydes

Nucleoside dialdehydes were obtained by periodate oxidation of adenosine, cytidine, guanosine, uridine or 6-azauridine in the presence of Dowex (1x8; CH3COO-). Reductive alkylation of daunorubicin with these dialdehydes in the presence of NaBH3CN produced a series of 3'-deamino-3'- (4-morpholino)daunorubicin or 13-(R,S)-dihydrodaunorubicin derivatives, the latter being mixtures of two diastereomers at 13-C atom. The morpholino- daunorubicin derivatives containing nucleic base moieties are less cytotoxic than cyanomorpholino-daunorubicin, morpholino-daunorubicin and even than the parent antibiotic.